Key facts

Active Substance
Autologous haptenised and irradiated cells derived from glioma
Therapeutic area
Oncology
Decision number
P/0226/2020
PIP number
EMEA-002661-PIP01-19
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of glioma
Route(s) of administration
Intradermal use
Contact for public enquiries

ERC Belgium

E-mail: lacroix@ercbelgium.eu
Tel. +32 81728610

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date

Decision

Share this page